Press release article from our research archive:
|
|
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy.
- Article from:
-
PR Newswire
- Article date:
-
October 11, 2007
|
Copyright informationCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Phase 2 monotherapy trial to be initiated by end of 2007 -
PRAGUE, Czech Republic, Oct. 11 /PRNewswire-FirstCall/ -- Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced today that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta therapy in patients with active relapsing multiple sclerosis (MS). These data will be presented tomorrow at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic.
The ongoing Phase 2, randomized, double blind, placebo-controlled clinical study, known as the CHOICE ...
Related newspaper, magazine, and journal articles:
|
BIOGEN IDEC FACES FACTS
The Boston Globe;
June 21, 2005 ;
567 words
...What does Biogen Idec Inc. think about the future of its...disease and pulled off the market. Ask Biogen Idec executives about Tysabri's prospects...You can learn more by watching what Biogen Idec does. The best example is the company...
|
|
Biogen Idec Inc. Current Market Review.
M2 Presswire;
April 24, 2007 ;
700+ words
......streetinvesting.com: Biogen Idec Inc. Current Market...losses, investors of Biogen Idec Inc. (NASDAQ:BIIB...American Markets. Biogen Idec Inc. was one of the...surface surrounding Biogen Idec Inc, which we feel...shareholder outcome, Biogen Idec Inc. ...
|
|
Fundamental Review for Biogen Idec Inc.
M2 Presswire;
February 15, 2007 ;
700+ words
......2007-Biotech News: Fundamental Review for Biogen Idec Inc.(C)1994-2007 M2 COMMUNICATIONS LTD...so it joined with Biogen to become Biogen Idec. The merged company is focused on developing...relapsed or low-grade B-cell NHL. While Biogen Idec's research pipeline is focused on ...
|
|
BIOGEN IDEC WARNS OF MS DRUG SHORTAGE
The Boston Globe;
May 7, 2004 ;
357 words
...Cambridge drug maker Biogen Idec Inc. yesterday warned of possible...the close of trading yesterday, Biogen Idec, the country's third-largest biotechnology...analysts, and the problems didn't stop Biogen Idec from reporting $355 million in Avonex...
|
|
Biogen Idec 4Q Profit Doubles
AP Online;
February 15, 2007 ;
566 words
...BOSTON - Biogen Idec Inc.'s fourth-quarter profit nearly...after patient deaths. Cambridge-based Biogen Idec earned $108.6 million, or 32 cents...acquisitions and a licensing agreement, Biogen Idec earned $184 million, or 53 cents per...
|
|
Biogen Idec Announces Webcast of Analyst Discussion at ASH.
PR Newswire;
December 5, 2003 ;
171 words
...Biogen Idec Inc. announced today that its analyst discussion of Biogen Idec related abstracts at the American Society of Hematology...begins at 10:00 am (ET) and is accessible through Biogen Idec's website, http://www.biogenidec.com/. (Logo: http...
|
|
Biogen Idec Swings to $43 Million Profit
AP Online;
April 27, 2005 ;
294 words
......AP Online 04-27-2005 Dateline: BOSTON Biogen Idec Inc. on Wednesday said it swung to a...sclerosis drug Tysabri. Cambridge-based Biogen Idec said net income for the January-March...Tysabri and other one-time charges, Biogen Idec's profit was $106 million, or 30 cents...
|
|
Biogen Idec to consider purchase offers; Interest from Icahn may have...
The Boston Globe;
October 13, 2007 ;
700+ words
...Biogen Idec Inc., the state's largest biotech company...disclosed he owns a 1 percent stake in Biogen Idec, won antitrust approval in August to...did not return a call seeking comment. Biogen Idec said its financial standing is healthy...
|
|
BIOGEN IDEC, SEEKING CLOUT IN CANCER DRUGS, TO BUY CONFORMA COMPANY MOVES...
The Boston Globe;
May 4, 2006 ;
700+ words
......as a provider of cancer treatments, Biogen Idec Inc. yesterday said it would buy Conforma Therapeutics Corp. of San Diego. Biogen Idec, one of the country's largest biotechnology...priorities. Mullen had previously said Biogen Idec would spend heavily to acquire new drug...
|
|
Biogen Idec and Elan Announce Update on Tysabri-R-.
Canadian Corporate News;
March 4, 2005 ;
647 words
......CCNMatthews via COMTEX) Biogen Idec (NASDAQ: BIIB) and Elan...combination with AVONEX(R) (Interferon beta-1a). -- To date, the companies...or rheumatoid arthritis. Biogen Idec has not received any reports...the market since 1996. -- Biogen Idec and Elan will work ...
|
|
Biogen Idec and Elan Submit Supplemental Biologics License Application to...
Canadian Corporate News;
September 26, 2005 ;
700+ words
......CCNMatthews via COMTEX) -- Biogen Idec (NASDAQ: BIIB) and Elan...add-on trial with AVONEX(R) (Interferon beta-1a) in MS; -- integrated...months for a standard review. Biogen Idec and Elan will submit a similar...president, Development, Biogen Idec. We are very ...
|
|
Biogen Idec Announces William H. Rastetter to Retire as Executive...
Canadian Corporate News;
December 7, 2005 ;
348 words
......7, 2005 (CCNMatthews via COMTEX) -- Biogen Idec (NASDAQ: BIIB) announced today that...President and Chief Executive Officer of Biogen Idec. I am proud of all that we have accomplished...as a Director of IDEC in 1997. About Biogen Idec Biogen Idec creates new standards ...
|
|
Biogen Idec's MS drug OK'd for Crohn's disease ; But approval includes...
The Boston Globe;
January 15, 2008 ;
400 words
...Federal regulators yesterday gave Biogen Idec Inc. good news about one of the Cambridge...the final decision was delayed because Biogen Idec and Elan Corp., the Irish company that...relatively modest benefit of Tysabri. Biogen Idec temporarily shelved the drug three years...
|
See all results.
Or, try our
Advanced Search.
|